SensoDetect advances Middle East expansion – introduces strategy for private school screening programs and SensoDetect-owned screening centers

SensoDetect AB (publ) announces the next phase of its previously communicated expansion in the Middle East. Last week, representatives of SensoDetect visited the region to continue discussions with private school groups, healthcare providers, and regional partners.

The delegation consisted of

- Dr. Mohamed Hussein Atwa Ahmed, Global Head of Clinical Research

- Ahmad Alosta, Regional Business Development and Quality Assurance (QA)

- Maher Almajzoub, External Partner in Business Development in the MENA region 

1. Private School Screening Programs (B2B)

SensoDetect will offer standardized neuro-auditory screening using the SensoDetect BERA platform directly to private school networks. The screening supports early identification of neurodevelopmental conditions and provides structured documentation for follow-up clinical evaluation when needed.

2. SensoDetect-Owned Screening Centers (Direct Access)

The company intends to establish SensoDetect-owned screening centers in selected cities. These centers will serve as regional hubs where families, clinics, and hospitals can access standardized screening and referral support under unified clinical and operational protocols.

“We see a clear and growing interest in early and structured screening in the region,” said PA Hedin, CEO of SensoDetect AB. “Last week’s visit provided a strong foundation for concrete next steps. Combining school-based programs with our own centers provides both accessibility and long-term presence.”

The ongoing autism study led by Dr. Fatimah continues according to plan. Upcoming data is expected to support continued development of screening and referral workflows in the region.

“There is strong commitment to objective evaluation at an early stage,” said Dr. Mohamed Hussein Atwa Ahmed, Global Head of Clinical Research, SensoDetect. “The SensoDetect BERA method aligns well with current initiatives in both the education and healthcare sectors.”

“For many families, understanding their child’s behavior can be confusing and stressful. The SensoDetect test brings clarity and hope; it helps parents see their child’s challenges in a new light and opens the door to early support,” said Mrs. Neven Ahmad, Journalist at Al-Thaerah Journal.

“Our discussions with school networks showed a strong openness to integrating structured screening as part of student health programs,” said Ahmad Alosta, Regional Business Development and Quality Assurance (QA). “This creates a clear pathway for scalable implementation in the private education sector.”

“Local coordination and continuity are essential for establishing trust and long-term adoption,” said Maher Almajzoub, External Partner in Business Development in the MENA region. “Our presence on the ground ensures that implementation will be practical, culturally aligned, and sustainable.”

SensoDetect will provide further updates as agreements are finalized, and implementation activities begin. Photos from the visit and school-based screening activities are attached to this release.

For more information or partnership inquiries, please contact:

PA Hedin, CEO Sensodetect AB

+46 (0)46 15 79 04
pa.hedin@sensodetect.com

SensoDetect AB is a MedTech AI company listed on the Spotlight Stock Market, focused on establishing the global standard for objective neuro-auditory brain screening. The company’s technology is based on more than 30 years of research in clinical psychoacoustics and neuroscience from Lund University and is protected by a strong international patent portfolio.

SensoDetect’s core platform uses brainstem auditory response patterns to objectively measure neural function in minutes. The method supports large-scale screening and clinical decision-making in conditions such as ADHD, autism spectrum disorder and other neurodevelopmental and psychiatric conditions—providing measurable signals where traditional diagnostic tools rely heavily on subjective assessment.

In recent years, the company has advanced from research to commercial deployment through strategic partnerships and clinical programs in Europe, the Middle East, and China. The latest generation of the system, including BERA 4.2 and integrated AI analysis, enables faster testing, greater scalability, and the ability to support national-level screening initiatives in healthcare, schools, and preventive medicine.

SensoDetect’s mission is to increase diagnostic accuracy, reduce waiting times, and support healthcare systems in managing the rapidly growing global need for mental and neurodevelopmental health evaluation. The company aims to make objective brain screening accessible at scale—improving outcomes for patients, families, and society.

More info at https://www.sensodetect.com/